The impactful RECOVER project officially came to an end in August 2023. In a series of video interviews, RECOVER project lead Em. Prof. Herman Goossens gives an overview of the project’s challenges and highlights.
Last week, the RECOVER Closing Conference took place in Zagreb, Croatia to honour the end of the project, this August. Not only was it an occasion to look back at the eventful past 3,5 years, but also to look towards the future and what is still to come.
We are proud to announce that one of the papers from our Social Science team is now one of BJGP’s most cited articles! This is a great achievement and a recognition of RECOVER’s contribution to COVID-19 research..
In November 2022, a new RECOVER paper was published titled ‘Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna’. The aim of the study was to investigate how targeted use of nirmatrelvir/ritonavir can complement vaccination and non-pharmaceutical interventions (NPIs), and mitigate the epidemic rebound expected when Zero-COVID ends.
In October 2022, a RECOVER paper was published on the outbreak of the SARS-CoV-2 Alpha variant in a Dutch primary school. The RECOVER team studied this outbreak, retrospectively and prospectively from December 2020 until February 2021, by using population-based screening. The aim was to get a better understanding of the disease severity and transmission of the Alpha variant.
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), one of our partners within the RECOVER Consortium, has recently published a new paper on COVID-19 data. The report focuses on a prospective, standardised, global dataset of patients that were hospitalised with COVID-19.
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), one of our partners within the RECOVER Consortium, has recently published a new paper on COVID-19 data. The report focuses on a prospective, standardised, global dataset of patients that were hospitalised with COVID-19.